195 search results for: Pathophysiology

Missing material
Content temporarily unavailable
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.

Missing material
Content temporarily unavailable
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.

Missing material
Content temporarily unavailable
ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes

Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.

Missing material
Content temporarily unavailable
Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.

Missing material
Content temporarily unavailable
IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.

Missing material
Content temporarily unavailable
How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares discusses how type 2 inflammation plays a critical role in a broad range of diseases across different organ systems.

Missing material
Content temporarily unavailable
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

Missing material
Content temporarily unavailable
CRSwNP Interactive Patient Case Tool

Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.

Missing material
Content temporarily unavailable
COPD and Asthma: What's the Difference and Is There a Link?

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

Missing material
Content temporarily unavailable
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

Missing material
Content temporarily unavailable
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.